Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 161

1.

Sodium dichloroacetate selectively targets cells with defects in the mitochondrial ETC.

Stockwin LH, Yu SX, Borgel S, Hancock C, Wolfe TL, Phillips LR, Hollingshead MG, Newton DL.

Int J Cancer. 2010 Dec 1;127(11):2510-9. doi: 10.1002/ijc.25499.

2.

Activation of mitochondrial oxidation by PDK2 inhibition reverses cisplatin resistance in head and neck cancer.

Roh JL, Park JY, Kim EH, Jang HJ, Kwon M.

Cancer Lett. 2016 Feb 1;371(1):20-9. doi: 10.1016/j.canlet.2015.11.023. Epub 2015 Nov 23.

PMID:
26607904
3.

Targeting of two aspects of metabolism in breast cancer treatment.

Gang BP, Dilda PJ, Hogg PJ, Blackburn AC.

Cancer Biol Ther. 2014;15(11):1533-41. doi: 10.4161/15384047.2014.955992.

4.

Dichloroacetate restores drug sensitivity in paclitaxel-resistant cells by inducing citric acid accumulation.

Zhou X, Chen R, Yu Z, Li R, Li J, Zhao X, Song S, Liu J, Huang G.

Mol Cancer. 2015 Mar 19;14:63. doi: 10.1186/s12943-015-0331-3.

5.

Dichloroacetate induces apoptosis in endometrial cancer cells.

Wong JY, Huggins GS, Debidda M, Munshi NC, De Vivo I.

Gynecol Oncol. 2008 Jun;109(3):394-402. doi: 10.1016/j.ygyno.2008.01.038. Epub 2008 Apr 18.

6.

Metabolic Modulation of Clear-cell Renal Cell Carcinoma with Dichloroacetate, an Inhibitor of Pyruvate Dehydrogenase Kinase.

Kinnaird A, Dromparis P, Saleme B, Gurtu V, Watson K, Paulin R, Zervopoulos S, Stenson T, Sutendra G, Pink DB, Carmine-Simmen K, Moore R, Lewis JD, Michelakis ED.

Eur Urol. 2016 Apr;69(4):734-44. doi: 10.1016/j.eururo.2015.09.014. Epub 2016 Feb 18.

PMID:
26433571
8.

Synergistic anticancer potential of dichloroacetate and estradiol analogue exerting their effect via ROS-JNK-Bcl-2-mediated signalling pathways.

Stander XX, Stander BA, Joubert AM.

Cell Physiol Biochem. 2015;35(4):1499-526. doi: 10.1159/000369710. Epub 2015 Mar 12.

9.

Dichloroacetate, a selective mitochondria-targeting drug for oral squamous cell carcinoma: a metabolic perspective of treatment.

Ruggieri V, Agriesti F, Scrima R, Laurenzana I, Perrone D, Tataranni T, Mazzoccoli C, Lo Muzio L, Capitanio N, Piccoli C.

Oncotarget. 2015 Jan 20;6(2):1217-30.

10.

Inactivation of the HIF-1α/PDK3 signaling axis drives melanoma toward mitochondrial oxidative metabolism and potentiates the therapeutic activity of pro-oxidants.

Kluza J, Corazao-Rozas P, Touil Y, Jendoubi M, Maire C, Guerreschi P, Jonneaux A, Ballot C, Balayssac S, Valable S, Corroyer-Dulmont A, Bernaudin M, Malet-Martino M, de Lassalle EM, Maboudou P, Formstecher P, Polakowska R, Mortier L, Marchetti P.

Cancer Res. 2012 Oct 1;72(19):5035-47. doi: 10.1158/0008-5472.CAN-12-0979. Epub 2012 Aug 3.

11.

Mito-DCA: a mitochondria targeted molecular scaffold for efficacious delivery of metabolic modulator dichloroacetate.

Pathak RK, Marrache S, Harn DA, Dhar S.

ACS Chem Biol. 2014 May 16;9(5):1178-87. doi: 10.1021/cb400944y. Epub 2014 Mar 25.

12.
13.

Effect of dichloroacetate on Lewis lung carcinoma growth and metastasis.

Kolesnik DL, Pyaskovskaya ON, Boychuk IV, Dasyukevich OI, Melnikov OR, Tarasov AS, Solyanik GI.

Exp Oncol. 2015 Jun;37(2):126-9.

PMID:
26112940
14.

The effect of dichloroacetate in canine prostate adenocarcinomas and transitional cell carcinomas in vitro.

Harting T, Stubbendorff M, Willenbrock S, Wagner S, Schadzek P, Ngezahayo A, Murua Escobar HM, Nolte I.

Int J Oncol. 2016 Dec;49(6):2341-2350. doi: 10.3892/ijo.2016.3720. Epub 2016 Oct 5.

PMID:
27748833
15.

Dichloroacetate metabolically targeted therapy defeats cytotoxicity of standard anticancer drugs.

Heshe D, Hoogestraat S, Brauckmann C, Karst U, Boos J, Lanvers-Kaminsky C.

Cancer Chemother Pharmacol. 2011 Mar;67(3):647-55. doi: 10.1007/s00280-010-1361-6. Epub 2010 May 26.

PMID:
20502900
16.

Targeting metabolism with arsenic trioxide and dichloroacetate in breast cancer cells.

Sun RC, Board PG, Blackburn AC.

Mol Cancer. 2011 Nov 18;10:142. doi: 10.1186/1476-4598-10-142.

17.

Dichloroacetate stimulates changes in the mitochondrial network morphology via partial mitophagy in human SH-SY5Y neuroblastoma cells.

Pajuelo-Reguera D, Alán L, Olejár T, Ježek P.

Int J Oncol. 2015;46(6):2409-18. doi: 10.3892/ijo.2015.2953. Epub 2015 Apr 6.

PMID:
25846762
18.

Dual-targeting of aberrant glucose metabolism in glioblastoma.

Shen H, Decollogne S, Dilda PJ, Hau E, Chung SA, Luk PP, Hogg PJ, McDonald KL.

J Exp Clin Cancer Res. 2015 Feb 5;34:14. doi: 10.1186/s13046-015-0130-0.

19.

Hypoxia enhances antitumor activity of dichloroacetate.

Kolesnik DL, Pyaskovskaya ON, Boichuk IV, Solyanik GI.

Exp Oncol. 2014 Dec;36(4):231-5.

PMID:
25537215
20.

[Possible mechanism of the selective action of the inhibitors of glycolysis in the endothelial cells and the human carcinoma cells in the culture].

Giliano NY, Bondarev GN, Konevega LV, Noskin LA, Zhurishkina EV, Alchinova IB.

Patol Fiziol Eksp Ter. 2014 Oct-Dec;(4):78-85. Russian.

PMID:
25980231

Supplemental Content

Support Center